CPB enters the back half of July with a quietly contradictory setup: short interest remains one of the highest readings in the packaged food universe, yet the stock has crept higher, borrowing costs have collapsed, and options traders are leaning bullish for the first time in months.
The most striking development in the lending market is not where short interest stands today — it's how fast conditions have normalized. Cost to borrow peaked above 24% in late June and touched 18% in early July. It has since fallen to under 2%. That is an 88% decline in a month, and it tells you that the acute borrow squeeze that briefly gripped CPB has fully unwound. Availability has loosened to 53% — still tight relative to the 52-week low of 21%, but meaningfully more relaxed than the sub-25% readings that persisted through most of June. Short interest itself pulled back sharply from a peak of around 54 million shares in late June to roughly 44 million now — an 11.5% decline month-over-month — though it remains elevated at nearly 15% of the free float. At three days to cover, any sustained covering could move the stock, but the borrow conditions no longer suggest an imminent squeeze.
Options tell a different story from the shorts. The put/call ratio has dropped to 0.73, more than one standard deviation below its 20-day average of 0.80, sitting near the lower end of the past year's range. That means call positioning has picked up relative to puts — a shift in tone from the more defensive stance options traders held through June and early July, when the PCR was running near 0.87. The contrast with the short book is notable: short sellers are still heavily committed, but options market participants are not adding downside hedges at the same rate. The two signals are pointing in opposite directions.
The Street remains unconvinced. The consensus is a Hold, with no Buy ratings visible, and the mean price target of $21.50 actually sits slightly below the current price of $22.34 — an unusual configuration that tells you the analyst community as a whole has not yet repriced for the stock's recent recovery. Stifel raised its target to $22 on July 22, maintaining a Hold, which is the most constructive action among recent moves. That contrasts with a wave of target cuts that followed the June 8 earnings print — BofA, Barclays, UBS, RBC, and Morgan Stanley all trimmed while keeping cautious ratings, and Bernstein went further, downgrading to Underperform. The EV/EBITDA multiple has ticked up to 8.8x, rising modestly over the past month as the stock recovered from its June lows, but the bull thesis in the analyst community remains thin. Factor scores confirm the caution: EPS momentum ranks in the bottom quintile of the universe on both 30- and 90-day windows, and forward earnings growth sits near its lowest percentile.
Ownership complicates the picture further. The Dorrance family — long-term controlling shareholders — holds more than 20% of the company across multiple vehicles, providing a structural floor to the register. BlackRock added nearly 12 million shares as of June 30, a meaningful move for a passive manager that typically reflects index rebalancing but adds notable weight to the buyer side of the register. The most recent insider activity, a pair of 100-share purchases by director Bennett Dorrance Jr. at $21.45 in early June, is more symbolic than material — the 90-day net buying of just $152,000 in value does not signal conviction at the executive level. The pattern of insider selling at much higher prices through late 2025 is a softer negative in the background.
The June 8 earnings release — the most recent comparable data point — produced a 2.1% one-day gain and a 2.9% five-day gain, a mild positive reaction that did not reverse the broader downtrend. The next print is scheduled for September 2. Between now and then, the tension worth watching is whether the sharp decline in short interest and borrowing costs represents genuine covering — shorts closing out — or simply a normalization of the borrow market after a squeeze, with positions still in place. The answer will be visible in the ORTEX daily estimates over the coming weeks.
See the live data behind this article on ORTEX.
Open CPB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
